HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Reinduction of neuroleptic malignant syndrome by lithium.

AbstractThe psychopharmacologic management of psychotic patients who have had neuroleptic malignant syndrome poses a dilemma for clinicians. Neuroleptic malignant syndrome can recur when neuroleptics are readministered, but there are equal numbers of reports of safe resumption of neuroleptic treatment in patients who have had the syndrome. In an effort to avoid reexposure to neuroleptics, the authors treated two bipolar patients who were clinically recovered from episodes of neuroleptic malignant syndrome with lithium alone. Both patients rapidly developed recurrent neuroleptic malignant syndrome after only 300 and 1,200 mg of lithium, respectively. Possible pathogenetic mechanisms are reviewed, although a definitive explanation for such a sudden and dramatic toxic effect is not available.
AuthorsV L Susman, G Addonizio (Affiliation: Department of Psychiatry, Cornell University Medical College, New York.)
JournalJournal of clinical psychopharmacology (J Clin Psychopharmacol) Vol. 7 Issue 5 Pg. 339-41 (Oct 1987) ISSN: 0271-0749 [Print] UNITED STATES
PMID3680605 (Publication Type: Case Reports, Journal Article)
Chemical References
  • Receptors, Dopamine
  • Lithium
Topics
  • Adult
  • Humans
  • Lithium (toxicity)
  • Male
  • Neuroleptic Malignant Syndrome (etiology)
  • Receptors, Dopamine (drug effects)
  • Recurrence

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password:


Research Interface PRO additionally includes drill-down to evidence, articles by author, export to Excel, FDA Link and mobile subscription:
1 year subscription, $45.00 USD